It induces myeloma cell apoptosis via modulating c-Maf stability and is intimately associated with occurrence of esophageal and breast cancer due to the deficiency of 17q25.1, possibly becoming a new cancer therapeutic target through modulating the AMPKa2-mTOR-HIF1a axis. Here, PRKAA2 is linked to cancer.